丹纳赫预计业绩将达先前指引高端

环球市场播报01-12

丹纳赫（Danaher）预计，受生物加工业务表现强劲的提振，第四财季收入增长和全年收益都将接近该公司先前业绩预期的上限。　　该公司表示，预计第四财季经调整的核心收入增长将接近其先前给出的低个位数百分比增长这一业绩预期的上限。　　该公司还表示，预计2025整个财年经调整后每股收益将接近先前预测的7.70美元至7.80美元区间的上限。　　首席执行官雷纳·布莱尔（Rainer Blair）表示：“...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2602546122?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-12 22:30","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2602546122","market":"hk","top_or_hot":-1,"title":"丹纳赫预计业绩将达先前指引高端","media":"环球市场播报","content":"<div>\n<p>丹纳赫（Danaher）预计，受生物加工业务表现强劲的提振，第四财季收入增长和全年收益都将接近该公司先前业绩预期的上限。\n　　该公司表示，预计第四财季经调整的核心收入增长将接近其先前给出的低个位数百分比增长这一业绩预期的上限。\n　　该公司还表示，预计2025整个财年经调整后每股收益将接近先前预测的7.70美元至7.80美元区间的上限。\n　　首席执行官雷纳·布莱尔（Rainer Blair）表示：“...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhi6588732.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>丹纳赫预计业绩将达先前指引高端</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n丹纳赫预计业绩将达先前指引高端\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-12 22:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhi6588732.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>丹纳赫（Danaher）预计，受生物加工业务表现强劲的提振，第四财季收入增长和全年收益都将接近该公司先前业绩预期的上限。\n　　该公司表示，预计第四财季经调整的核心收入增长将接近其先前给出的低个位数百分比增长这一业绩预期的上限。\n　　该公司还表示，预计2025整个财年经调整后每股收益将接近先前预测的7.70美元至7.80美元区间的上限。\n　　首席执行官雷纳·布莱尔（Rainer Blair）表示：“...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhi6588732.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2355687059.USD","symbol_name":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-01-12/doc-inhhamhi6588732.shtml","article_id":"2602546122","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602546122","pubTimestamp":1768228200,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"丹纳赫（Danaher）预计，受生物加工业务表现强劲的提振，第四财季收入增长和全年收益都将接近该公司先前业绩预期的上限。\n　　该公司表示，预计第四财季经调整的核心收入增长将接近其先前给出的低个位数百分比增长这一业绩预期的上限。\n　　该公司还表示，预计2025整个财年经调整后每股收益将接近先前预测的7.70美元至7.80美元区间的上限。\n　　首席执行官雷纳·布莱尔（Rainer Blair）表示：“我们对第四财季生物加工业务的持续强劲表现以及生命科学和诊断业务收入好于预期感到尤其满意。”\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：李桐","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU1923621640.USD":"Natixis Thematics Water R/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU2063271972.USD":"富兰克林创新领域基金","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","BK4581":"高盛持仓","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4121":"生命科学工具和服务","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","DHR":"丹纳赫","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0820562030.AUD":"ALLIANZ INCOME AND GROWTH \"AMH2\" (AUDHDG) H2 INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4585":"ETF&股票定投概念","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD"},"translate_title":"Danaher expects results to reach the high end of previous guidance","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1.5},"content_text":"丹纳赫（Danaher）预计，受生物加工业务表现强劲的提振，第四财季收入增长和全年收益都将接近该公司先前业绩预期的上限。\n　　该公司表示，预计第四财季经调整的核心收入增长将接近其先前给出的低个位数百分比增长这一业绩预期的上限。\n　　该公司还表示，预计2025整个财年经调整后每股收益将接近先前预测的7.70美元至7.80美元区间的上限。\n　　首席执行官雷纳·布莱尔（Rainer Blair）表示：“我们对第四财季生物加工业务的持续强劲表现以及生命科学和诊断业务收入好于预期感到尤其满意。”\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：李桐","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602546122","isCrawlerRequest":true}